Bakri Sophie J

Macaron Marie-Michele, Al Sabbakh Nader, Shami M Zaid, Akrobetu Dennis, Bourdakos Natalie E, Abdulsalam Fatma A M et al.

This study found anti-VEGF and combination therapies for PDR offer better visual outcomes and neovascularization regression than PRP, suggesting they are viable alternatives based on patient factors.

Bressler Neil M, Freund K Bailey, Bakri Sophie J, Kim Judy E, Ferrara Daniela, Brittain Christopher et al.

Repeated 0.1mL intravitreous lampalizumab injections for geographic atrophy were studied. Key finding: No significant IOP increase or higher glaucoma/ocular hypertension rates than sham over one year. Clinical relevance: Supports low IOP risk for larger injection volumes.

Shah Saumya M, Boopathiraj Nithya, Starr Matthew R, Dalvin Lauren A, AbouChehade Jackson, Damento Gena et al.

This study found anti-VEGF injections for AMD didn't increase glaucoma risk. However, treated eyes with glaucoma needed more medications and showed faster visual field loss than some controls, requiring careful monitoring.

Mansukhani Sasha A, Barkmeier Andrew J, Bakri Sophie J, Iezzi Raymond, Pulido Jose S, Khanna Cheryl L et al.

Mansukhani Sasha A, Barkmeier Andrew J, Bakri Sophie J, Iezzi Raymond, Pulido Jose S, Khanna Cheryl L et al.

This study found vitrectomy significantly increases the 10-year risk of primary open-angle glaucoma (POAG). Clinically, this highlights the need for long-term POAG screening after vitrectomy.

Bakri Sophie J, Omar Ahmed F, Iezzi Raymond, Kapoor Kapil G

Repeated DEX injections for RVO-CME are feasible but require vigilant monitoring for common side effects like elevated eye pressure and cataract progression.

Dedania Vaidehi S, Bakri Sophie J

Anti-VEGF injections for nAMD can cause sustained IOP elevation in 3.45-11.6% of patients, sometimes requiring surgery. Clinicians should monitor for this multifactorial complication, especially with risk factors.

Bakri Sophie J, Couch Steven M, McCannel Colin A, Edwards Albert O

This study found same-day triple therapy for wet AMD maintained vision and reduced macular thickness, potentially decreasing anti-VEGF injection frequency, offering a new treatment approach.

Bakri Sophie J, McCannel Colin A, Edwards Albert O, Moshfeghi Darius M

Intravitreal ranibizumab can cause severe, persistent ocular hypertension requiring medical treatment, highlighting the need for post-injection IOP monitoring.

Bakri Sophie J, Snyder Melissa R, Reid Joel M, Pulido Jose S, Ezzat Mohamed K, Singh Ravinder J

This rabbit study found intravitreal ranibizumab has a 2.88-day vitreous half-life, shorter than bevacizumab, with no systemic or fellow-eye detection, suggesting a favorable safety profile.

Amselem Luis, Montero Javier, Diaz-Llopis Manuel, Pulido Jose S, Bakri Sophie J, Palomares Paula et al.

Intravitreal bevacizumab in two OIS patients reduced iris neovascularization and macular edema, suggesting it may be a useful treatment for these complications.

Bakri Sophie J, Snyder Melissa R, Reid Joel M, Pulido Jose S, Singh Ravinder J

This rabbit study found intravitreal bevacizumab (1.25mg) has a vitreous half-life of 4.32 days, maintaining therapeutic levels for 30 days, with minimal systemic exposure, guiding dosing for retinal conditions.

Beer Paul M, Bakri Sophie J, Singh Ravinder J, Liu Weiguo, Peters George B, Miller Michael

This study found intravitreal triamcinolone's elimination half-life is ~18.6 days in non-vitrectomized eyes, lasting ~3 months. Vitrectomy shortens this, impacting dosing and glaucoma risk.